Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters
 

Santa Rosa, California Clinical Trials

A listing of Santa Rosa, California clinical trials actively recruiting patient volunteers.

RESULTS

Found (4) clinical trials

G1T38 a CDK 4/6 Inhibitor in Combination With Osimertinib in EGFR-Mutant Non-Small Cell Lung Cancer

This is a study to investigate the potential clinical benefit of G1T38 as an oral therapy in combination with osimertinib in patients with EGFR mutation-positive metastatic non-small cell lung cancer. The study is an open-label design, consists of 2 parts: safety, pharmacokinetic, and dose-finding portion (Part 1), and randomized portion ...

Phase

3.4 miles

Learn More »

Combination Study of SV-BR-1-GM in Combination With Pembrolizumab

This is an open-label, single arm study of the SV-BR-1-GM regimen in patients with metastatic or locally recurrent breast cancer who have failed at least one line of therapy. Patients may enter this study directly or may roll-over from Study WRI-GEV-007, "A Phase I/IIa Study of SV-BR-1-GM in Metastatic or ...

Phase

3.4 miles

Learn More »

Brentuximab Vedotin and Nivolumab With or Without Ipilimumab in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma

PRIMARY OBJECTIVES: I. To determine the maximum tolerated dose (MTD) and dose limiting toxicities (DLT) of the combinations of brentuximab vedotin and ipilimumab, brentuximab vedotin and nivolumab, and brentuximab vedotin, ipilimumab, and nivolumab. (Phase I) II. To evaluate the complete response (CR) rate for the regimens of brentuximab vedotin and ...

Phase

3.4 miles

Learn More »

Galinpepimut-S in Combination With Pembrolizumab in Patients With Selected Advanced Cancers

This is a Phase 1/2, open-label, non-comparative, multicenter, multi-arm study of the Wilms Tumor-1 (WT1)-targeting multivalent heteroclitic peptide immunotherapeutic vaccine galinpepimut-S in combination with the programmed death-1 (PD1) inhibitor pembrolizumab in patients with selected advanced cancers. This study will assess the efficacy and safety of galinpepimut-S and pembrolizumab and investigate ...

Phase

3.4 miles

Learn More »